Better process development is creating industry benchmarks for bioprocessing.
Suppliers indicate prices for single-use equipment are likely to increase.
Biopharma companies are outsourcing more jobs to cut costs.
Automation and disposables continue to reduce human error.
Biopharma companies on both sides of the Atlantic ship more of their assay testing to outside service providers.
While the United States and Europe still dominate, CMOs and CROs based in emerging markets continue to capture market share.
Is there enough talent to go around?
There are significant differences between small molecules and biologics fill/finish capacity.
Outsourcing is taking on a greater role in the biopharmaceutical manufacturing industry.
Biopharma continues to adopt single-use technologies, but also seeks more innovation and improvements in products.